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The surface M protein of group A streptococci renders the organisms resistant 
to phagocytosis in the nonimmune host. In the immune host, antibodies against 
M  protein  opsonize  the  organisms,  which  are  then  readily  phagocytosed and 
killed.  These observations have  served for many years as the basis for studies 
directed toward the development of a safe and effective M protein vaccine that 
would prevent streptococcal pharyngitis and thus rheumatic fever. Because group 
A streptococci contain several different antigens that are immunologically cross- 
reactive  with  host  tissues  (1-3),  one  of the  major  concerns  has  been  that  M 
protein vaccines may contain harmful antigens able to cause, rather than prevent, 
rheumatic  fever.  Indeed,  recent  studies  in  our  laboratory  have  shown  that  a 
highly purified pepsin extract of type 5  M protein  (pep M5) evoked antibodies 
that  cross-reacted with  a  sarcolemmal  membrane  protein  of human  heart  (3). 
The purified heart-reactive antibodies opsonized type 5 streptococci, indicating 
their reactivity with the surface M protein. 
Having demonstrated the presence of heart cross-reactive antigens within the 
pepsin-derived fragment of type 5 M protein, we undertook the present study to 
determine  the  immunogenicity  of two  chemically  synthesized  peptides  repre- 
senting only limited regions of the native pep M5 molecule. The two synthetic 
peptides are copies of the amino terminal region of pep M5, representing residues 
1-20 [S-M5(1-20)] and 20-40 [S-M5(20-40)]. We present evidence that neither 
peptide reacts with purified heart cross-reactive antibodies raised against intact 
pep M5.  When covalently linked to tetanus toxoid and  emulsified in complete 
Freund's  adjuvant,  S-M5(1-20),  but  not  S-M5(20-40),  is  shown  to  evoke high 
titers of type-specific, opsonic antibodies in rabbits; none of the animals developed 
antibodies that were cross-reactive with sarcolemmal membranes of human heart. 
Our data show that  immunization  with a  chemically synthesized peptide repre- 
senting a limited region of the M protein molecule evokes type-specific, protective 
antibodies without eliciting tissue cross-reactive antibodies. 
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Materials and  Methods 
Extraction and Purification of M Protein.  M protein (pep M) was purified to homogeneity 
from limited peptic digests of types 5,  6,  19,  and 24 group A streptococci as previously 
described (3-5). 
Chemical Synthesis of S-M5(1-20) and S-M5(20-40).  Polypeptides identical to the amino- 
terminal  amino acid  sequence  of pep  M5  (5),  consisting  of 20  amino acids  each  and 
overlapping at only the 20th residue, were synthesized by an automated peptide synthes- 
izer at Peninsula  Laboratories, Inc., San Carlos, CA and purified by high performance 
liquid  chromatography (HPLC).  The  peptides  were  sequenced  by automated  Edman 
degradation  with  a  Beckman  Sequenator  (model  890C;  Beckman  Instruments,  Inc., 
Fullerton, CA), as previously described (4-6). 
Conjugation of Synthetic Peptides to Tetanus Toxoid.  Before conjugation to the peptides, 
the tetanus toxoid was first conjugated to L-lysine.  10 mg of the toxoid was added to 1.0 
ml of 0.025% glutaraldehyde in 0.1  M NaHCOs and rotated at ambient temperature for 
1  h.  t-lysine was added to a final concentration of 0.2 M and the mixture was rotated for 
an additional  48  h.  The conjugate was washed with  5 vol of 0.1  M  NaHCO3 using an 
Amicon flow cell equipped  with  a  PM10  filter (Amicon Corp.,  Danvers,  MA).  Lysine 
conjugation was confirmed by increased reactivity with  the ninhydrin  reagent (7),  and 
total protein was quantitated according to the principles of Lowry et al. (8).  1 mg of the 
toxoid and 1 mg of the synthetic peptide were then added to 1 ml of 0.1% glutaraldehyde 
in  0.1  M NaHCO.~ and rotated for 48 h at ambient temperature. The concentration of 
glutaraldehyde was then increased to 0.5%, the mixture was rotated for an additional 5 
d,  and  the  conjugate  was  washed  with  0.1  M  NaHCO~ as  described  above.  In  some 
experiments, the synthetic polypeptides were covalently linked to poly-L-lysine (mol wt, 
70,000; Sigma Chemical Co., St.  Louis, MO) in the presence of carbodiimide (hydrogen 
cyanomide; Sigma Chemical Co.), as previously described (9,  10). 
hnmunization  Procedures.  Two groups of three New Zealand white rabbits were injected 
with 100 ~g s.c. of the respective tetanus toxoid-conjugated synthetic peptide, which had 
been emulsified in complete Freund's adjuvant (9,  10). Blood was obtained immediately 
before the initial injection and at 2-wk intervals thereafter. At 4 and 10 wk, the animals 
were boosted with  100 #g of the conjugated peptide in 0.02 M phosphate, 0.15 M NaCI, 
pH  7.4  (phosphate-buffered  saline  [PBS].  Rabbit  antisera  against  the  native  pep  M5 
molecule were similarly prepared by immunizing with 100 ~g doses of pep M5 (5). 
Assays for Pep M Antibodies.  All sera were tested for the presence of pep M antibodies 
by an enzyme-linked immunosorbent assay (ELISA) as previously described (9, 11). ELISA 
inhibition  assays were  performed by incubating a  constant  dilution  of antiserum  with 
increasing concentrations of synthetic polypeptides or pep M5 as soluble inhibitors (11). 
Opsonic  antibodies  were  detected  by  in  vitro  opsonophagocytic  assays,  as  described 
elsewhere (4, 6,  12). 
Detection of Heart Cross-reactive Antibodies.  Indirect immunofluorescence tests for heart 
cross-reactive antibodies were performed using purified sarcolemmal membranes (13) or 
thin sections of human heart as described elsewhere (3). 
Purification of Heart-reactive Antibodies from Pep M5 Antisera.  Because previous studies 
have shown that the heart-reactive antibodies raised in rabbits against pep M5 also cross- 
reacted  with  type  19  M  protein  (3),  we  used  pep  M19  that  was covalently linked  to 
cyanogen bromide-activated Sepharose 4B (Pharmacia Fine Chemicals, Piscataway, N  J) to 
affinity purify heart-reactive antibodies from the pep M5 antiserum, as described else- 
where (3). 
Results 
Amino Acid Sequences of S-M5(1-20) and S-M5(20-40).  The primary structures 
of the  chemically synthesized  peptides  were determined  by automated  Edman 
degradation to assure their identity with the corresponding regions of the native 
pep M5 molecule. The sequence of S-M5(1-20) was found to be: DALE, SEYER, AND BEACHEY  BRIEF  DEFINITIVE REPORT  1729 
5  10  15  20 
Ala-Val-Thr-  Lys-Gly-Thr-  lle-Asn-Asp-  Pro-Gln-  Ala-Ala-Lys-Glu-Ala-Leu-Asp-Lys-Tyr. 
The S-M5(20-40) sequence was: 
20  95  30  35  40 
Tyr-Glu-  Leu-Glu-Asn-His-Asp-Leu-  Lys-Thr-Asn-Asn-Glu-  Gly-  Leu-Lys-Thr-Glu-Asn-Thr-Gly. 
Both are identical to  the corresponding regions of pep  M5,  according to  the 
amino acid sequence determined in our laboratories (5), but are slightly different 
from the amino acid sequence previously reported for pep M5 by Manjula and 
Fischetti (14). 
Absence of Hea rt Cross-reactive Antigenic Determinants on S-M5(1-20) and S-M5(20- 
40).  Initial experiments were designed to determine whether the chemically 
synthesized peptides of type 5 M protein contained antigens able to bind either 
heart cross-reactive or type-specific antibodies raised against pep M5. The pep 
M5 heart-reactive rabbit antiserum (3)  was fractionated by affinity chromatog- 
raphy  into  type-specific and  heart  cross-reactive  antibodies,  as  described  in 
Materials and Methods. The type-specific fraction reacted in high titer with pep 
M5, but not with the heart-reactive epitope of pep M 19, as measured by ELISA, 
and was also unreactive in  immunofluorescence tests using sarcolemmal mem- 
branes from human heart. The heart-reactive fraction of the pep M5 antiserum 
reacted with pep  M5  and pep  M19,  as measured by ELISA, and also reacted 
with human heart sarcolemmai membranes by immunofluorescence (3). 
To determine the antigenic specificity of the synthetic peptides of type 5  M 
protein, ELISA inhibition tests were performed using S-M5(1-20), S-M5(20-40), 
and pep M5 as soluble inhibitors. Inhibition assays were performed with heart- 
reactive (Fig.  1A)  and  non-heart-reactive (Fig.  1B)  fractions of the pep  M5 
rabbit antiserum, using pep M5 as the immobilized antigen. Binding of heart- 
reactive antibodies to pep M5 was not inhibited at all by S-M5(1-20) or S-M5(20- 
40),  but  was readily inhibited by the homologous pep  M5  antigen (Fig.  1A). 
However, the binding of type-specific non-heart-reactive antibodies was inhib- 
ited 56%  by S-M5(1-20),  but not by S-M5(20-40) at the highest concentration 
tested (Fig.  1 B). These data suggested that neither of the two synthetic peptides 
contained antigenic determinants able to bind heart-reactive antibodies raised 
against the pep M5 molecule. Also, S-M5(1-20), but not S-M5(20-40), contained 
antigens able to inhibit type-specific antibodies directed against pep M5. 
Immunogenicity of Synthetic Peptides of Type 5 Pep M.  Because previous studies 
had shown that a synthetic peptide of type 24 pep M was immunogenic in rabbits 
after conjugation to poly-L-lysine (9), we first immunized rabbits with  100 ug of 
either S-M5(1-20) or S-M5(20-40), covalently linked to poly-L-lysine and emulsi- 
fied in complete Freund's adjuvant.  None of the rabbits developed antibodies 
against pep M5 as measured by either ELISA or in vitro opsonophagocytic tests. 
Two  groups  of rabbits  were  then  immunized  with  the  synthetic  peptides 
covalently linked to tetanus toxoid and emulsified in complete Freund's adjuvant. 
All three rabbits immunized with S-M5(1-20) developed type-specific antibody 
titers against pep M5 as early as 4 wk after the initial injection, as measured by 
ELISA (Fig.  2A).  At 6  wk, all  three animals also developed opsonic antibody 
titers against type 5  streptococci (Fig.  2B), as measured by timed phagocytosis 
tests. These results were later confirmed by indirect bactericidal tests using type 1730  DALE,  SLYER,  AND  BEACHEY  BRIEF  DEFINITIVE  REPORT 
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F]CURE  l.  ELISA inhibition of heart-reactive and  type-specific pep M5 antibodies by pep 
M5, S-M5(1-20) and S-M5(20-40).  Increasing concentrations of pep M5 (O), S-M5(1-20) (A), 
and  S-M5(20-40) (Q) were used to inhibit the binding of heart cross-reactive antibodies (A) 
and type-specific antibodies (B) to immobilized pep M5. The highest concentration of pep M5 
tested was 10 t~g/m] and the highest concentration of the synthetic polypeptides tested was 20 
•g/ml. 
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FICURE 2.  ELISA and  opsonic antibody  titers  in  serum  from  rabbits  immunized  with  S- 
M5(1-20) covalently linked to tetanus toxoid. Three rabbits (&, 0, ") were immunized with 
100/~g S-M5(1-20) conjugated to tetanus toxoid and emulsified in complete Freund's adjuvant. 
Booster injections of 100/~g of the conjugated peptide in PBS were given as indicated by the 
arrows. The assays were performed as described in Materials and Methods. 
5 streptococci. None of the S-M5(1-20) immune sera reacted with pep M6, pep 
M 19, or pep M24, as measured by ELISA, nor did they opsonize types 6,  19, or 
24 streptococci.  None of three rabbits immunized with S-M5(20-40) developed 
antibodies against  type 5  pep  M  as measured  by ELISA or opsonophagocytic 
tests. 
Absentee of Heart-reactive Antibodies in the Sera of Rabbits hnmunized with S-M5(1- 
20).  To test directly whether S-M5(1-20) contained potentially harmful  heart- 
reactive antigenic determinants, immunofluorescence tests were done using each 
of the three S-M5(1-20)-immune rabbit sera against thin sections of human heart DALE, SEYER, AND  BEACHEY  BRIEF  DEFINITIVE REPORT  1731 
(4)  and  purified  sarcolemmal  membranes  (3).  None  of the  sera  reacted  with 
either of these tissue preparations. Also, none of the immune sera reacted in the 
ELISA with the heart cross-reactive determinant of type 19 pep M (3). 
Discussion 
Because  of the  fear  that  pep  M  vaccines  may  contain  tissue  cross-reactive 
antigens that might cause, rather than prevent, rheumatic fever, there has been 
considerable  interest  in  defining  the  minimum peptide  structure  of pep  M 
necessary to elicit type-specific protective immunity. This approach allows for 
the  disposal  of the  majority  of the  M  molecule that  may  contain  potentially 
harmful tissue cross-reactive determinants. Having previously demonstrated the 
presence  of  at  least  one  heart  cross-reactive  epitope  on  the  pepsin-derived 
fragment of type 5 M protein (3), we undertook the present study to determine 
the antigenic specificity and protective immunogenicity of two chemically syn- 
thesized peptides of pep M5. Initial experiments showed that neither of the two 
peptides, S-M5(1-20)  nor S-M5(20-40),  contained antigens capable of reacting 
with purified heart  cross-reactive antibodies raised  against the native pep  M5 
molecule. S-M5(1-20),  but not S-M5(20-40),  retained type-specific epitopes, as 
demonstrated by ELISA  inhibition  assays.  When  covalently linked to  tetanus 
toxoid,  S-M5(1-20)  evoked type-specific, protective antibodies in all  three  im- 
munized rabbits without producing heart cross-reactive antibodies. 
These data are consistent with previous experiments in our laboratory  that 
showed  that  a  cyanogen  bromide-derived  peptide  of type  24  pep  M,  or  its 
chemically synthesized analogue,  consisting of only 35  amino acids covalently 
linked to polylysine, also produced protective immunity in laboratory animals (9, 
10).  Taken together, these studies indicate that only a  limited region of the M 
molecule coupled to the appropriate carrier is sufficient to produce protective 
immunity against group A streptococci, thus limiting the total amount of protein 
injected and minimizing the possibility of producing potentially harmful tissue 
cross-reactive immunity. Continued isolation and identification of natural pep- 
tides and even chemical synthesis of such peptides from various pep M may yield 
a  safe  and  effective  vaccine  against  a  number  of potentially  rheumatogenic 
serotypes of Streptococcus pyoge~es. 
Summary 
We determined the antigenic specificity and protective immunogenicity of two 
chemically synthesized peptides of type 5 streptococcal M protein. The synthetic 
peptides, designated S-M5(1-20) and S-M5(20-40), represent the amino-terminal 
amino acid sequence of the native pepsin-extracted M5 molecule, which is known 
to contain at least one heart cross-reactive epitope. Initial  studies showed that 
neither of the  synthetic  peptides was  able  to bind purified heart-reactive  M5 
antibodies. In addition, S-M5(1-20), but not S-M5(20-40), contained type-specific 
antigenic determinants as measured by enzyme-linked immunosorbent inhibition 
assays. When covalently linked to tetanus toxoid, S-M5(1-20), but not S-M5(20- 
40), evoked significant levels of type-specific, opsonic (and presumably protective) 
antibodies in rabbits without evoking heart cross-reactive antibodies. 
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